不同COVID-19危重症变异株流行期与其他下呼吸道感染的临床结局比较
该研究为瑞典斯德哥尔摩基于健康登记的人群队列研究,纳入2016年1月1日至2022年9月15日ICU收治的成人,比较野生型、Alpha、Delta、Omicron四个COVID-19变异株期与其他下呼吸道感染(LRTI)患者的结局。院内死亡率从LRTI队列的28%(n=665)到Delta队列的35%(n=77);校正病因特异性风险比(CSHR)与LRTI队列相比,野生型1.33(95%CI 1.16-1.53)、Alpha 1.53(1.28-1.82)、Delta 1.70(1.30-2.24)、Omicron 1.59(1.24-2.02)。出院存活者中,COVID-19组出院后死亡率较低(1-3%),LRTI组为9%,再入院风险也较低(CSHR 0.42-0.68);所有COVID-19队列在危重症前后相比DAAH均多于LRTI队列。结论提示COVID-19危重症院内死亡风险增高,但出院存活者远期结局较其他LRTI更轻。
要点
- ICU收治的COVID-19各变异株期患者院内死亡风险均高于其他LRTI:校正CSHR野生型1.33(1.16-1.53)、Alpha 1.53(1.28-1.82)、Delta 1.70(1.30-2.24)、Omicron 1.59(1.24-2.02)。
- 院内死亡率LRTI队列28%(n=665),Delta队列最高35%(n=77);野生型1421例、Alpha 551例、Delta 190例、Omicron 223例、LRTI 2380例。
- 出院存活者中,COVID-19组出院后死亡率1-3%,低于LRTI组的9%;再入院风险也更低(CSHR 0.42-0.68)。
- 所有COVID-19队列在危重症前后相比DAAH均多于LRTI队列。
适用人群与场景
- 2016年1月1日至2022年9月15日期间在瑞典斯德哥尔摩ICU收治的成人,包括COVID-19野生型、Alpha、Delta、Omicron期患者及其他下呼吸道感染(LRTI)患者。
研究设计与关键结果
- 研究类型为基于健康登记的人群队列研究,纳入ICU收治成人:野生型1421例、Alpha 551例、Delta 190例、Omicron 223例、LRTI 2380例。
- 院内死亡率从LRTI队列的28%(n=665)到Delta队列的35%(n=77)。
- 与LRTI队列相比,院内死亡校正病因特异性风险比(CSHR):野生型1.33(95%CI 1.16-1.53),Alpha 1.53(1.28-1.82),Delta 1.70(1.30-2.24),Omicron 1.59(1.24-2.02)。
- 出院存活者中,COVID-19组出院后死亡率1-3%,LRTI组为9%;再入院风险CSHR为0.42-0.68。
- 所有COVID-19队列在危重症前后相比DAAH均多于LRTI队列。
证据类型、等级与局限
- 证据类型:基于健康登记的人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It is yet to be better understood how outcomes during and after the critical illness potentially differ between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants from other lower respiratory tract infections (LRTIs). We aimed to compare outcomes in adults admitted to an intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) during the Wild-type, Alpha, Delta, and Omicron periods with individuals admitted with other LRTI.
METHODS: Population-based cohort study in Stockholm, Sweden, using health registries with high coverage, including ICU-admitted adults from 1 January 2016 to 15 September 2022. Outcomes were in-hospital mortality, 180-day post-discharge mortality, 180-day hospital readmission, 180-day days alive and at home (DAAH), and incident diagnoses registered during follow-up.
RESULTS: The number of ICU admitted individuals were 1421 Wild-type, 551 Alpha, 190 Delta, 223 Omicron, and 2380 LRTI. In-hospital mortality ranged from 28% (n = 665) in the LRTI cohort to 35% (n = 77) in the Delta cohort. The adjusted cause-specific hazard ratio (CSHR) compared with the LRTI cohort was 1.33 (95% confidence interval [CI] 1.16-1.53) in the Wild-type cohort, 1.53 (1.28-1.82) in the Alpha cohort, 1.70 (1.30-2.24) in the Delta cohort, and 1.59 (1.24-2.02) in the Omicron cohort. Among patients discharged alive from their COVID-19 hospitalization, the post-discharge mortality rates were lower (1-3%) compared with the LRTI cohort (9%), and the risk of hospital readmission was lower (CSHRs ranging from 0.42 to 0.68). Moreover, all COVID-19 cohorts had compared with the LRTI cohort more DAAH after compared with before the critical illness.
CONCLUSION: Overall, COVID-19 critical was associated with an increased hazard of in-hospital mortality, but among those discharged alive from the hospital, less severe long-term outcomes were observed compared with other LRTIs.
参考来源
- Hedberg P, Baltzer N, Granath F, et al. Clinical outcomes during and beyond different COVID-19 critical illness variant periods compared with other lower respiratory tract infections. Crit Care. 2023. PMID: 37932793. doi:10.1186/s13054-023-04722-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。